Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10

Saokar, Anuradha; Gee, Michael S.; Islam, Tina; Mueller, Peter R.; Harisinghani, Mukesh G.

doi:10.1016/j.clinimag.2009.09.008

« Previous Next »Clinical Imaging
Volume 34, Issue 6 , Pages 448-452, November 2010

Appearance of primary lymphoid malignancies on lymphotropic nanoparticle-enhanced magnetic resonance imaging using ferumoxtran-10

Anuradha Saokar
- Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Michael S. Gee
- Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Tina Islam
- Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- Corresponding author. Center for Molecular Imaging Research, Department of Radiology, Division of Abdominal Imaging and Intervention, Boston, MA 02114, USA. Tel.: +1 617 724 4266; fax: +1 617 726 4891.
Peter R. Mueller
- Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Mukesh G. Harisinghani
- Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- Department of Radiology, Division of Abdominal Imaging and Intervention, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

Received 28 August 2009; accepted 28 September 2009. published online 15 January 2010.

Abstract

Patients with pathologically confirmed lymphoma/leukemia were retrospectively identified from a large single-institution phase III clinical trial with ferumoxtran-10. Five (2.3%) of 220 patients had lymphoid malignancies involving lymph nodes. A subset of patients (n=27) with biopsy-proven nodal metastases from genitourinary or breast cancer was selected as control group. Ferumoxtran-10 enhancement patterns and signal-to-noise ratios of lymph nodes involved by metastases and lymphoid malignancy were assessed. Like nodal metastases, nodes involved by lymphoid malignancies demonstrate persistent high T2*-signal intensity on lymphotropic nanoparticle-enhanced magnetic resonance imaging.

Keywords: Lymphoma, Superparamagnetic iron oxide nanoparticles, Ferumoxtran-10, MRI, Lymphotropic nanoparticle-enhanced MRI